General Information

Inform has been approved for the prediction of breast cancer. It is a gene-based test which identifies the presence or absence of increased copies of the HER-2/neu gene, a gene known to have an increased presence in a particularly aggressive form of breast cancer.

Clinical Results

In studies with early breast cancer patients, 69% of the women who tested positive for the HER-2/neu gene survived five years after surgery compared with 97% of patients with negative test results.